Comparative effects of antiplatelet, antico- agulant, or combined therapy in patients with valvular and nonvalvular atrial brillation: a randomized multicenter study. J Am Coll Cardiol. 2004;44(8):1557-1566. 73. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in non-rheumatic atrial brillation in primary care: randomised controlled trial comparing two intensities of coumarin with aspirin. BMJ. 1999;319(7215):958-964. 74. Morocutti C, Amabile G, Fattapposta F, et al; SIFA (Studio Italiano Fibrillazione Atriale) Investigators. Indobufen ver- www.chestpubs.org CHEST / 141 / 2 / FEBRUARY, 2012 SUPPLEMENT e573S thrombin inhibitor in atrial brillation (SPORTIF) trials. Am Heart J. 2006;152(5):967-973. 105. Clinical review for Pradaxa, NDA 22-512. In: United States Food and Drug Administration; 2010:96. 106. Hansen ML, S rensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial brillation. Arch Intern Med. 2010;170(16):1433-1441. 107. Dentali F, Douketis JD, Lim W, Crowther M. Combined aspirin-oral anticoagulant therapy compared with oral anti- coagulant therapy alone among patients at risk for cardio- vascular disease: a meta-analysis of randomized trials. Arch Intern Med. 2007;167(2):117-124. 108. Vandvik PO, Lincoff AM, Gore JM, et al. Primary and sec- ondary prevention of cardiovascular disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians evidence-based clinical prac- tice guidelines. Chest. 2012;141(2)(suppl):e637S-e668S. 109. Iakovou I, Schmidt T, Bonizzoni E, et al. Incidence, predic- tors, and outcome of thrombosis after successful implanta- tion of drug-eluting stents. JAMA. 2005;293(17):2126-2130. 110. Serruys PW, Strauss BH, Beatt KJ, et al. Angiographic fol- low-up after placement of a self-expanding coronary-artery stent. N Engl J Med. 1991;324(1):13-17. 111. Roubin GS, Cannon AD, Agrawal SK, et al. Intracoronary stenting for acute and threatened closure complicating per- cutaneous transluminal coronary angioplasty. Circulation. 1992;85(3):916-927. 112. Foley JB, Brown RI, Penn IM. 